A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-center Trial to Evaluate the Efficacy and Safety of ONO-1110 in Patients With Social Anxiety Disorder
Latest Information Update: 24 Mar 2025
At a glance
- Drugs ONO 1110 (Primary)
- Indications Anxiety disorders
- Focus Therapeutic Use
- Sponsors Ono Pharmaceutical
Most Recent Events
- 19 Mar 2025 Status changed from not yet recruiting to recruiting.
- 06 Feb 2025 New trial record